Clinical Trial Update: A Phase 1/2, First-in-Human, Open Label, Dose Escalation Study Of A CSP Targeting Functional Antibody in Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 first-in-human open-label dose-escalation study of a CSP-targeting functional antibody in solid tumors completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Cancer Metastatic
• Ovarian Serous Adenocarcinoma
• Ovarian Serous Cystadenocarcinoma
• Pancreatic Ductal Adenocarcinoma
• Solid Tumor

Drugs mentioned

• CSP-targeting functional antibody

Snippet

Sponsor: ZielBio, Inc. | Conditions: Solid Tumor, Adult, Pancreatic Ductal; Adenocarcinoma | Phase 1, Phase 2 | Status: COMPLETED